

e-Therapeutics plc

05:32 11 Jun 2015


e-Therapeutics bullish on discovery platform

e-Therapeutics (LON:ETX) remains upbeat on its new discovery platform that it said is achieving productivity rates well above the norm. Molecule selection and testing across seven projects had suggested more than 25% of screened compounds were both active and more potent than any previously reported. "For example, initial results from our most recent project, which sought potent small molecule inhibitors of TNF α , a major inflammatory cytokine, produced a yield rate of potent molecules above 40%, even after initial toxicity screening," said acting chairman and chief executive Malcolm Young. These yield rates are much higher than published rates for conventional drug discovery, he added. Cytokines are small cells that affect the behaviour of other cells. In its clinical programmes, e-therapeutics recently dosed its first patient for a Phase 1b trial in pancreatic and hepatocellular cancers. The final patient has also been enrolled in a US study into brain cancer. This cohort is being dosed at 36 mg/kg with one of the group presently on their seventh cycle at this dose level. "Unlike the UK trial, there have been no dose-limiting toxicities determined at the current dosage, although the patients have experienced similar short-term side effects to those observed in the UK," Young said. "With the progress we are making both in the clinical programmes and in discovery, we expect another exciting year, he concluded. Shares rose 3% to 41p.

Price: 3.85

Market Cap: £10.36 m

1 Year Share Price Graph



January 2019 August 2019 January 2020

Share Information

Code: ETX

Listing: AIM

52 week	High	Low
	5.5	1.25

Sector: Pharma & Biotech

Website: www.etherapeutics.co.uk

Company Synopsis:

We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.

Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

 Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).